Joseph G. Pressey · Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Follow
Article1 min read·Published Jan 2023Older

Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2023 · 1 min read

In brief

In brief

This study identifies two molecularly distinct Ewing sarcoma subsets based on IGF1R localization and replication stress levels, with differing responses to IGF1R and WEE1 inhibitors. Combined inhibition showed efficacy across both tumor types, suggesting a biomarker-driven approach for treatment selection in relapsed/metastatic disease.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Purpose: Targeted cancer therapeutics have not significantly benefited patients with Ewing sarcoma with metastatic or relapsed disease. Understanding the molecular underpinnings of drug resistance can lead to biomarker-driven treatment selection. Experimental Design: Receptor tyrosine kinase (RTK) pathway activation was analyzed in tumor cells derived from a panel of Ewing sarcoma tumors, including primary and metastatic tumors from the same patient. Phospho-RTK arrays, Western blots, and IHC were used. Protein localization and the levels of key markers were determined using immunofluorescence. DNA damage tolerance was measured through PCNA ubiquitination levels and the DNA fiber assay. Effects of pharmacologic inhibition were assessed in vitro and key results validated in vivo using patient-derived xenografts. Results: Ewing sarcoma tumors fell into two groups. In one, IGF1R was predominantly nuclear (nIGF1R), DNA damage tolerance pathway was upregulated, and cells had low replication stress and RRM2B levels and high levels of WEE1 and RAD21. These tumors were relatively insensitive to IGF1R inhibition. The second group had high replication stress and RRM2B, low levels of WEE1 and RAD21, membrane-associated IGF1R (mIGF1R) signaling, and sensitivity to IGF1R or WEE1-targeted inhibitors. Moreover, the matched primary and metastatic tumors differed in IGF1R localization, levels of replication stress, and inhibitor sensitivity. In all instances, combined IGF1R and WEE1 inhibitio

Statements in this article

  1. Ewing sarcoma tumors fall into two molecularly defined groups based on IGF1R localization, replication stress levels, and drug sensitivity patterns.

    ResearchResults
  2. Tumors with predominantly nuclear IGF1R have upregulated DNA damage tolerance pathways, low replication stress, low RRM2B levels, and high levels of WEE1 and RAD21.

    ResearchResults
  3. Tumors with nuclear IGF1R are relatively insensitive to IGF1R inhibition.

    ResearchResults
  4. Tumors with membrane-associated IGF1R have high replication stress, high RRM2B levels, low levels of WEE1 and RAD21, and are sensitive to IGF1R or WEE1-targeted inhibitors.

    ResearchResults
  5. Matched primary and metastatic tumors from the same patient differ in IGF1R localization, levels of replication stress, and inhibitor sensitivity.

    ResearchResults
  6. Combined IGF1R and WEE1 inhibition shows activity across both tumor subsets.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.